未来食品&农业 |慕恩生物 让专业的人聚在一起, 合成生物学与绿色生物制造产业同行♥ J 【SynBioCon】 获 悉， 3月23日 ， 慕恩生物、蘑米生物与广东省农业科学院动物科学研究所 正式签署战略合作协议。各方将围绕 微生物科 技与畜禽养殖产业链 的深度融合，聚焦畜禽合成生物技术的研发与应用转化，协同推进畜禽养殖生物制造的产业化进程。 当下，畜禽养殖业正面临着提质增效与绿色转型的双重挑战，而合成生物技术为解决种源"卡脖子"问题、开发新型饲料原料及添加剂提供了全新 的路径。 据介绍，此次合作构建了"科研引领+平台支撑+产业转化"的三维协同的模式： 三方合力推进合成生物技术在畜禽领域的科研突破与成果落地。 此外，合作三方还将深度整合产学研资源，组建联合团队对接广东省农业科技创新主攻方向，积极 申报参与 国家及省市重点科技项目，以科技 创新驱动畜禽养殖生物制造产业新标杆的打造，为粤港澳大湾区建设具有全球影响力的生物制造创新高地、服务国家"大农业观"与"大食物观"战 略注入新动能。 大家都在看： 慕恩生物入选2025年WIPO全球奖30强！拥有全球最大商业菌种库！ 国投、慕恩生物、湖南国资！背后多重身影!蘑米 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 北京首鋼朗澤科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）╱證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。您閱覽本文件，即代表您知悉、 接納並向本公司、其獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據呈交香港公司註冊處處長註冊的本公 司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (i) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件中 的資料作出任何投資決定； (ii) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、其獨家保薦人、整體協調 人、顧問或包銷團成員須在 ...

This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its sole sponsor, overall coordinator, advisers or members of the underwriting syndicate that: (the "Company") (A joint stock company incorporated in the People's Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Ko ...

Core Viewpoint - Fungifuture, a synthetic biology new materials company, has completed a financing round of several tens of millions of RMB, led by Yuan Yi Capital, to expand the production of bio-based mycelium materials and build its team [2][3]. Group 1: Company Overview - Fungifuture specializes in the research and production of mycelium fiber materials, with a comprehensive R&D center for the entire process of mycelium material development and production [3]. - The company has developed a unique liquid fermentation technology for mass production, overcoming issues associated with traditional solid fermentation methods [4]. Group 2: Market Potential - The global market for bio-based new materials is expected to exceed $30 billion by 2025, with a compound annual growth rate of approximately 8% [3]. - Mycelium materials are rapidly replacing traditional materials in key sectors such as packaging, construction, and fashion due to their superior performance [3]. Group 3: Technological Advantages - Fungifuture's core technologies include unique liquid fermentation for uniform fiber production, gene editing for optimizing fiber structure, and a production system that eliminates chemical additives [4]. - The production process significantly reduces energy costs by 50%, wastewater treatment costs by 60%, and carbon emissions by 70%, aligning with ESG standards [4]. Group 4: Industry Outlook - The founder and CEO of Fungifuture, Jin Lina, emphasizes that bio-based materials are entering a period of rapid growth, with the potential to replace petroleum-based materials [5]. - The company aims to optimize costs and penetrate the market comprehensively, contributing to a green transformation in the materials industry [5]. Group 5: Investment Perspective - Yuan Yi Capital views Fungifuture's liquid fermentation technology as a breakthrough that enables the transition of mycelium from laboratory materials to scalable industrial raw materials [6]. - The market demand for mycelium materials is expected to grow explosively, with Fungifuture positioned uniquely in terms of technology and product differentiation [6].

Core Viewpoint - Huaxi Biological Technology Co., Ltd. reported a significant transformation from scale expansion to quality improvement in its operations, achieving notable profit growth despite a decline in revenue [1][4]. Financial Performance - The company achieved total revenue of 4.217 billion yuan in 2025, a year-on-year decrease of 21.49% [2]. - Net profit attributable to shareholders reached 291 million yuan, an increase of 67.03% compared to the previous year [2]. - The net profit after deducting non-recurring gains and losses was 188 million yuan, reflecting a 75.28% year-on-year growth [2]. - The weighted average return on equity was 4.17%, up 1.62 percentage points from the previous year [2]. Business Strategy - The decline in revenue was attributed to systematic structural optimization in skin science and nutrition science innovation, focusing on core brands and product categories [2][3]. - The company is shifting its marketing strategy from scale-oriented to efficiency-oriented, enhancing brand communication and resource allocation [2][3]. Operational Efficiency - The company streamlined overlapping departments and optimized its organizational structure, resulting in a management expense reduction of over 10% year-on-year [3]. - Sales expenses decreased by over 30% in 2025, contributing to improved profitability despite revenue pressure [3]. Research and Innovation - The company is focusing on research in glycoscience and cell biology, enhancing its capabilities in the industrialization of bioactive materials and regenerative materials [3]. - Digitalization and AI technologies are being integrated into production, supply chain management, and internal operations to improve overall operational efficiency [3]. Future Outlook - The company aims to continue its transformation towards quality growth, leveraging synthetic biology and industrialization capabilities to enhance core competencies and sustainable development [4].

Core Viewpoint - Huaxi Biological Technology Co., Ltd. reported a significant transformation in its operational strategy, shifting from scale expansion to quality improvement, resulting in enhanced profitability despite a decline in revenue [1][4]. Financial Performance - In 2025, the company achieved total operating revenue of 4.217 billion yuan, a year-on-year decrease of 21.49% [1]. - The net profit attributable to shareholders was 291 million yuan, reflecting a year-on-year increase of 67.03% [1]. - The net profit after deducting non-recurring gains and losses reached 188 million yuan, up 75.28% year-on-year [1]. - The weighted average return on net assets was 4.17%, an increase of 1.62 percentage points compared to the previous year [1]. Business Strategy - The decline in revenue was primarily due to systematic structural optimization in skin science and nutrition science innovation businesses, focusing on core brands and key categories [2]. - The company reduced investment in less efficient brands and projects, concentrating resources on areas with technological foundations and product accumulation [2]. - Management expenses decreased by over 10% year-on-year, contributing to profit growth through effective cost control [2]. - Sales expenses dropped by over 30% year-on-year, further enhancing profitability amid revenue pressure [2]. Research and Innovation - The company is advancing research in glycoscience and cell biology, focusing on extracellular matrix regulation mechanisms for aging intervention and tissue regeneration [3]. - It is enhancing the industrialization capability of bioactive substances and regenerative materials through a synthetic biology research and development system [3]. - Digitalization and AI technologies are being applied in production, supply chain management, and internal operations to improve overall operational efficiency [3]. Future Outlook - The 2025 performance reflects the results of organizational optimization, business focus, technological innovation, and digital empowerment [4]. - The company aims to continue building core capabilities around synthetic biology technology and industrialization to enhance operational quality and sustainable development [4].

Core Viewpoint - The article discusses the policies implemented by the Heilongjiang Provincial Government to support the high-quality development of the biomanufacturing industry, emphasizing the promotion of biochemicals and materials with high technological content and added value [2][5]. Group 1: Enhancing Technological Innovation Capabilities - Support for the construction of innovation platforms in biomanufacturing, encouraging collaboration between enterprises and research institutions [6]. - Financial support for key technology research projects in biomanufacturing, including innovative drugs and biochemicals [6]. - Incentives for enterprises to increase R&D investment, with subsidies based on the amount invested [6]. - Support for the establishment of pilot testing platforms to facilitate the connection between R&D and production [6]. - Encouragement of technology transfer activities, with financial assistance for contracts exceeding 1 million yuan [6]. Group 2: Promoting Industry Expansion and Quality Improvement - Financial support for new biomanufacturing projects with fixed asset investments of 20 million yuan or more, providing up to 5 million yuan in subsidies [7]. - Support for equipment upgrades in biomanufacturing enterprises to enhance production efficiency [7]. - Encouragement for enterprises to adopt digital technologies, with financial incentives for recognized digital workshops and smart factories [7]. - Promotion of industry collaboration through the establishment of innovation alliances and research institutes [7]. Group 3: Supporting Key Sector Development - Focus on strengthening the biopharmaceutical sector with financial support for new drugs and high-end medical devices at various clinical trial stages [8]. - Encouragement for the development of new food products, providing rewards for approved new food ingredients [8]. - Promotion of biochemicals, with incentives for products achieving significant sales [8]. Group 4: Increasing Resource Assurance - Support for the construction of biomanufacturing parks and infrastructure improvements [9]. - Assurance of key resources for biomanufacturing projects, including energy and land [10]. - Strengthening financial services for biomanufacturing enterprises, including support for listing and innovative financing products [10]. - Enhancement of intellectual property protection for biomanufacturing innovations [10]. - Development of talent in the biomanufacturing sector through educational initiatives and support for high-level talent recruitment [10].

Group 1 - The company, Zhongmu Co., stated that some of its product manufacturing technologies align with characteristics of synthetic biology [2]

Group 1 - The company Zhongmu Co., Ltd. (600195.SH) indicated on its investor interaction platform that some of its product manufacturing technologies align with characteristics of synthetic biology [1]

Core Insights - The Chinese nutrition and health industry is experiencing a surge in IPO activities, indicating a shift from local operations to global expansion and a focus on scientific validation [4][5]. IPO Developments - In 2025, several companies in the nutrition and health sector are set to go public, covering the entire supply chain from raw materials to manufacturing and branding [4]. - Dongpeng Beverage plans to list on the Hong Kong Stock Exchange in early 2026, aiming to raise over HKD 10.1 billion, marking the largest IPO in the non-alcoholic beverage sector in Hong Kong history [4]. - Xianle Health is advancing its H-share listing while optimizing its global CDMO platform by divesting non-core assets [4]. - Ruoyuchen has submitted its application to the Hong Kong Stock Exchange, focusing on its proprietary brand FineNutri to transition from a service provider to a brand owner [4]. - Other companies like Jiyuan Group and Hengmei Health are also pursuing listings to enhance their production capacities and market presence [4][5]. Regulatory Updates - The National Market Supervision Administration has released several guidelines and regulations affecting the health and nutrition sector, including the review of special medical formula food production licenses and the management of live-streaming e-commerce [6][7]. - New regulations have been introduced to ensure compliance in the marketing of health products, including a ban on certain food sales in live-streaming environments [6]. Market Trends - There is a notable increase in demand for health supplements, with sales of ginseng and other tonic products rising by 55% year-on-year during the New Year holiday [17]. - The import of medical and health products has also seen significant growth, with a 70.4% increase in imports in Hubei province in 2025 [17]. Industry Insights - The current wave of capital influx is not merely for financing but signals a critical transition in the industry towards scientific validation and global operations [4]. - Companies with genuine research capabilities, compliant product systems, and international perspectives are expected to gain a competitive edge in high-quality development [4].